OncoMatch/Clinical Trials/NCT04840264
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Is NCT04840264 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Docetaxel and Oxaliplatin for metastatic gastric adenocarcinoma.
Treatment: Docetaxel · Oxaliplatin · Fluorouracil — This is a multi-center, non-randomized, 3-cohort, phase II trial, evaluating a triplet combination of docetaxel, oxaliplatin and fluorouracil for gastric cancer with peritoneal carcinomatosis and inoperable malignant bowel obstruction.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Esophageal Carcinoma
Ovarian Cancer
Biomarker criteria
Excluded: HER2 (ERBB2) amplification
HER-2 amplification or overexpression
Excluded: HER2 (ERBB2) overexpression
HER-2 amplification or overexpression
Excluded: MMR expression deletion
mismatch repair protein expression deletion (dMMR)
Excluded: MSI high
genetic testing suggestive of high microsatellite instability (MSI-H)
Disease stage
Metastatic disease required
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: combination regimen containing all the study drugs (docetaxel, oxaliplatin, 5-fluorouracil)
treated by a combination regimen containing all the study drugs
Lab requirements
Blood counts
Hb≥60g/L, WBC ≥4×10E9/L, ANC≥2×10E9/L, PLT≥100×10E9/L
Kidney function
Cr≤ Upper Normal Limit(UNL)
Liver function
Tbil≤1.5 UNL, AST≤1.5 UNL, ALT≤1.5 UNL, ALP≤1.5 UNL
Hb≥60g/L, WBC ≥4×10E9/L, ANC≥2×10E9/L，PLT≥100×10E9/L; Cr≤ Upper Normal Limit(UNL); Tbil≤1.5 UNL,AST≤1.5 UNL, ALT≤1.5 UNL, ALP≤1.5 UNL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify